MediPharm Labs Corp (MEDIF)
0.0536
0.00 (0.00%)
USD |
OTCM |
Jun 14, 16:00
MediPharm Labs Gross Profit Margin (Quarterly): 27.13% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 27.13% |
December 31, 2023 | 24.05% |
September 30, 2023 | 28.42% |
June 30, 2023 | 8.92% |
March 31, 2023 | 6.62% |
December 31, 2022 | 3.76% |
September 30, 2022 | -16.39% |
June 30, 2022 | -12.20% |
March 31, 2022 | -8.26% |
December 31, 2021 | -86.59% |
September 30, 2021 | -34.44% |
Date | Value |
---|---|
June 30, 2021 | -152.5% |
March 31, 2021 | -12.37% |
December 31, 2020 | -408.1% |
September 30, 2020 | -214.0% |
June 30, 2020 | 15.89% |
March 31, 2020 | -98.13% |
December 31, 2019 | 30.78% |
September 30, 2019 | 34.01% |
June 30, 2019 | 35.94% |
March 31, 2019 | 31.27% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-408.1%
Minimum
Dec 2020
35.94%
Maximum
Jun 2019
-41.37%
Average
-2.25%
Median
Gross Profit Margin (Quarterly) Benchmarks
Venus Concept Inc | 66.63% |
Acasti Pharma Inc | -- |
Aurinia Pharmaceuticals Inc | 88.04% |
Edesa Biotech Inc | -- |
Lexaria Bioscience Corp | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -25.01% |
Return on Assets | -20.60% |
Return on Invested Capital | -24.17% |
Profit Margin (Quarterly) | -36.96% |
Operating Margin (Quarterly) | -38.12% |
Return on Net Operating Assets | -29.15% |